IL3RA and CD4+/CD56+ hematodermic neoplasm: A recent preclinical study explored the targeting of CD123 in BPDCN using IMGN632, showing significant anti-leukemic effects, even at a dose of IMGN362 10-fold lower than the anticipated therapeutically active dose [132].